Caviton5 mg

Caviton is used as an adjunct in the management of symptoms related to chronic cerebrovascular insufficiency and its cognitive consequences. Evidence for its efficacy is moderate/limited compared to major, first-line drug classes for these conditions, so it is generally used as a supportive or add-on therapy rather than as monotherapy for a diagnosed neurological disease.

• Guideline/label-supported adjunct use: Symptomatic relief of mild-to-moderate memory and cognitive impairment (e.g., difficulty concentrating, forgetfulness) associated with chronic cerebrovascular insufficiency, where Caviton is registered as a prescription pharmaceutical (as in Bangladesh and several other markets).
• Adjunct use: Post-stroke cognitive and neurological sequelae, used together with standard stroke rehabilitation and secondary-prevention therapy, not as a substitute for them.
• Adjunct use: Age-related cognitive decline and vascular-type dementia symptoms, as a supportive measure alongside standard dementia care.
• Off-label use (commonly reported, not formally approved): Tinnitus and some inner-ear circulatory complaints, and as a nootropic supplement for general cognitive support in some countries; robust high-quality evidence for these uses is lacking, and such use should only be under medical advice.

Note: Caviton is not an FDA-approved prescription drug in the United States (its US regulatory status is that of an unapproved/unauthorized dietary-supplement ingredient with an active FDA safety warning); the indications above reflect its status as a registered prescription medicine in markets such as Bangladesh.

Each tablet of Vinpocetine contains Vinpocetine USP/BP as the sole active pharmaceutical ingredient, commonly available in strengths of 5 mg and 10 mg for oral use. Tablets also contain standard pharmaceutical excipients (e.g., binders, fillers, disintegrants, coating agents) that do not affect the therapeutic action of Vinpocetine.

Caviton is a semisynthetic derivative of vincamine, an alkaloid originally extracted from the leaves of the lesser periwinkle plant (Vinca minor). It is classified pharmacologically as a nootropic agent and cerebral vasodilator with phosphodiesterase-1 (PDE1) inhibitory activity.

Caviton is used clinically to improve cerebral blood flow and oxygen/glucose utilization in brain tissue, and is marketed in a number of countries, including Bangladesh, as a prescription oral tablet for cognitive and cerebrovascular symptoms. It is not approved as a drug by the US FDA; in the United States its sale has instead been the subject of an FDA safety warning, chiefly because of teratogenicity signals seen in animal studies.

Nootropic agent / Cerebral vasodilator (Phosphodiesterase-1 [PDE1] inhibitor)

Mechanism

Vinpocetine selectively inhibits calcium/calmodulin-dependent phosphodiesterase type 1 (PDE1), leading to increased intracellular cyclic GMP levels in vascular smooth muscle, which produces cerebral-selective vasodilation and improves regional cerebral blood flow. Vinpocetine also blocks voltage-sensitive sodium channels, which is thought to contribute to a neuroprotective effect during ischemia, and it has been shown to modestly inhibit platelet aggregation and reduce blood viscosity, further supporting microcirculatory flow.

Pharmacokinetics

Oral bioavailability of Vinpocetine is low (approximately 7%) and is increased when taken with food. Peak plasma concentration is reached roughly 1 hour after an oral dose. Vinpocetine is extensively metabolized in the liver, predominantly to apovincaminic acid (AVA), an active metabolite. The elimination half-life of Vinpocetine is approximately 4-5 hours, and metabolites are excreted mainly via the kidneys.

Caviton tablets should be taken orally with food or immediately after a meal to enhance absorption and minimize stomach upset. Swallow the tablet whole with water; do not crush or chew unless the product labeling specifically permits it. Doses should be spaced evenly through the day (e.g., three times daily) as advised by the physician, and Caviton should not be stopped or the dose changed abruptly without medical advice.

Overall, published high-quality clinical interaction data for Caviton are limited; the interactions above are largely theoretical or based on mechanism, and patients should inform their physician of all other medicines and supplements they are taking before starting Caviton.

Caviton is generally well tolerated at recommended doses. Reported adverse effects are usually mild and transient.

• Dizziness and headache
• Mild hypotension (low blood pressure) and facial flushing
• Nausea, dry mouth, and other mild gastrointestinal upset
• Sleep disturbances (insomnia or drowsiness)
• Rarely, tachycardia or palpitations

Patients should seek medical advice if side effects with Caviton are severe or persistent.

Pregnancy: Caviton is contraindicated during pregnancy. Animal reproduction studies have shown teratogenic effects (fetal harm) with Caviton, and it should not be used by women who are pregnant or planning pregnancy.

Lactation: It is not established whether Caviton passes into human breast milk. Given the pregnancy safety signal and limited data, Caviton should be avoided during breastfeeding; a physician should be consulted if use is being considered in a breastfeeding mother.

Use Caviton with caution in patients with a history of hypotension, cardiac arrhythmia, or unstable cardiovascular disease, as noted under Contraindications. Caution is also advised in patients with hepatic or renal impairment, as clinical experience in these groups is limited.

Because robust, high-quality clinical trial evidence supporting Caviton is more limited than for major, guideline-endorsed drug classes, it should be used as an adjunct under medical supervision rather than as a substitute for established therapies for stroke, dementia, or cardiovascular disease. Patients should be reassessed periodically to confirm continued benefit.

In the United States, Caviton is not an FDA-approved drug; regulatory status varies by country, and patients should only use Caviton products obtained through legitimate, regulated pharmaceutical channels on a physician's advice.

Data on deliberate overdose with Caviton are limited. Based on its known pharmacology, overdose may be expected to cause exaggerated side effects such as pronounced hypotension, dizziness, and cardiac rhythm disturbances. If overdose with Caviton is suspected, seek immediate medical attention or contact a poison control center/emergency services; do not attempt to manage a suspected overdose at home. Supportive and symptomatic treatment should be provided by medical professionals as needed.

Store Caviton at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Caviton is commonly used in older adults for its labeled indications; no specific dose adjustment is generally required, but caution is advised given a higher likelihood of concurrent cardiovascular disease and polypharmacy.

Renal impairment: Data on dose adjustment of Caviton in renal impairment are limited; use with caution and medical supervision.

Hepatic impairment: Since Caviton is extensively metabolized by the liver, use with caution in patients with hepatic impairment; dose reduction or closer monitoring may be warranted.

Pediatric population: See Pediatric Uses.

Treatment with Caviton is typically trialed for several weeks (commonly 4-12 weeks) before the physician reassesses whether meaningful benefit is being achieved. If benefit is seen, Caviton may be continued longer-term under periodic medical review; if no benefit is apparent, continued use should be reconsidered.

Nootropic agents; Cerebral vasodilators; Phosphodiesterase-1 (PDE1) inhibitors

Vinpocetine acts primarily by selectively inhibiting phosphodiesterase type 1 (PDE1), raising intracellular cyclic GMP in cerebral vascular smooth muscle and producing selective cerebral vasodilation, which increases cerebral blood flow and improves oxygen and glucose delivery to brain tissue. Vinpocetine also blocks voltage-sensitive sodium channels (contributing to neuroprotection under ischemic conditions) and mildly inhibits platelet aggregation, together supporting its use as an adjunct for cerebrovascular and cognitive symptoms.

Safety and efficacy of Caviton in children and adolescents (under 18 years) have not been established. Caviton is not recommended for use in the pediatric population outside of a physician-directed clinical context, and it should not be given to children without specific medical advice.